Johns Hopkins School of Medicine

Employer-Reported Respiratory Illness Increased 4,000% in 2020, Signaling Effects from COVID-19, Allsup Reports

Retrieved on: 
Monday, March 21, 2022
FICA, Social Security Disability Insurance, Death, SSDI, Johns Hopkins School of Medicine, Coronavirus, BLS, Overalls, Social, Social Security Administration, Geist, First Time, American Veterans Disabled for Life Memorial, Bureau of Labor Statistics, Social Security, COVID-19, Tax, GLOBE, Scar, Physical, Income, Medicare, PDF, COVID, Allsup, Disability, Insurance, Health insurance

In a report from the U.S. Bureau of Labor Statistics, the number of respiratory cases rose from 10,800 in 2019 to 428,700 in 2020.

Key Points: 
  • In a report from the U.S. Bureau of Labor Statistics, the number of respiratory cases rose from 10,800 in 2019 to 428,700 in 2020.
  • Respiratory illnesses comprised 79% of all employer-reported illnesses in 2020 compared to 8.5% in 2019.
  • This enormous spike in reported cases of respiratory illnesses strongly suggests the impact of the COVID-19 pandemic, said T.J. Geist, Principal Advocate for Allsup.
  • As weve come to understand in these past two years, the coronavirus and its variants have serious implications for the lungs and overall respiratory system.

Graybug Vision to Host Virtual R&D Day on March 30, 2022

Retrieved on: 
Monday, March 21, 2022
Private Securities Litigation Reform Act, Retina, University, Form 10-K, MA, Investor, Pediatric ophthalmology, Forward-looking statement, ID, Clinical research, Annual report, University of California, Irvine School of Medicine, University of California, SEC, Doctor of Philosophy, Sunitinib, Webcast, Medical director, U.S. Securities and Exchange Commission, Johns Hopkins School of Medicine, Technology, Karger Publishers, VEGF, Reno 1868 FC, Institute, COVID-19, MBA, University of Nevada, Reno School of Medicine, GLOBE, Fellow, Disease management, Division, CHOC, Security (finance), Pharmaceutical industry, Medicine, Ophthalmology, MD

BALTIMORE, March 21, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced that it will host a virtual Investor R&D Day from 11 a.m. - 12:45 p.m.

Key Points: 
  • BALTIMORE, March 21, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced that it will host a virtual Investor R&D Day from 11 a.m. - 12:45 p.m.
  • Additionally, Graybug will provide a strategic outlook.
  • Attendees may also participate by dialing (844) 955-2748 (domestic) or (929) 517-0407 (international) and entering the conference ID# 9785187.
  • Graybug is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases.

Tevard Biosciences licenses mRNA Amplifier technology from Johns Hopkins University

Retrieved on: 
Thursday, March 31, 2022
People, Heart, Mike Hopkins (basketball), Johns Hopkins University, Muscular dystrophy, Silencer (firearm), Lists of diseases, Father, Oligonucleotide, Biotechnology, RNA transfection, Amplifier, Bloomberg, Dravet syndrome, CEO, RNA, Molecular biology, Johns Hopkins School of Medicine, Technology, Gene editing, Haploinsufficiency, Jeremy Coller, Doctor of Philosophy, Mutation, Gene, Degenerative disease, Bloomberg Distinguished Professorships, SAB, Department, Genetics, Protein, Whitehead Institute, MIT, Pharmaceutical industry, Vaccine

CAMBRIDGE, Mass., March 31, 2022 /PRNewswire/ -- Tevard Biosciences, the pioneer of tRNA-based treatments for severe genetic diseases, today announced an agreement to exclusively license "mRNA Amplifier" technology from the Johns Hopkins University. The technology will help form the basis of Tevard's third platform for addressing diseases in which a mutation has caused a reduction in or loss of a vital protein.

Key Points: 
  • New platform provides additional avenue for treating severe genetic diseases, joins Tevard's tRNA-based platforms in broadly applicable suite of technologies
    CAMBRIDGE, Mass., March 31, 2022 /PRNewswire/ -- Tevard Biosciences , the pioneer of tRNA-based treatments for severe genetic diseases, today announced an agreement to exclusively license "mRNA Amplifier" technology from the Johns Hopkins University.
  • The technology will help form the basis of Tevard's third platform for addressing diseases in which a mutation has caused a reduction in or loss of a vital protein.
  • While the company's first two platforms employ RNA-based molecules called tRNAs, the new mRNA Amplifier platform is based around specially engineered proteins.
  • Tevard Biosciences is pioneering mRNA-modulating therapies to cure a broad range of genetic diseases.

Employer Direct Healthcare Adds Two Noteworthy Advisors from Johns Hopkins University

Retrieved on: 
Tuesday, March 29, 2022
Public policy, LinkedIn, World Health Organization, Johns Hopkins University, Leadership, MSN, Johns Hopkins School of Medicine, Public health, Clinical research, Caregiver, Johns Hopkins, Health care, Research, World, EDH, CEO, Health, Surgical oncology, Technology, Physician, Patient safety, Policy, Solution, NCI, Patient, Pharmaceutical industry, Medicine, Health insurance, The New York Times, DALLAS

DALLAS, March 29, 2022 /PRNewswire/ -- Employer Direct Healthcare (EDH), a leader in specialty healthcare solutions, today announced the addition of two thought leaders at Johns Hopkins to the team advising the company's overarching approach to quality standards for its comprehensive end-to-end oncology and SurgeryPlus® solutions. Dr. Martin Makary, M.D., M.P.H., surgeon and public policy researcher at Johns Hopkins University, and Christi Walsh, MSN, CRNP, Director of Clinical Research and Nurse Practitioner at Johns Hopkins Medicine will share their clinical expertise and passion for public health and policy reform in support of EDH's mission of providing high-quality care at fair prices.

Key Points: 
  • EDH is collaborating with Johns Hopkins University on a research study to demonstrate the impact of surgeon selection on cost and health outcomes.
  • "Healthcare delivery, policy, and technology advancements are happening at a pace we've never seen before" stated John Zutter, CEO, Employer Direct Healthcare.
  • Employer Direct Healthcare is a market-leading healthcare services business providing high-quality and cost-efficient solutions for self-funded employers and their members.
  • For more information and the latest updates about Employer Direct Healthcare, visit EDHC.com and follow us on LinkedIn .

Laekna Therapeutics Appoints Jeff Porter, Ph.D. as Chairman of Scientific Advisory Board

Retrieved on: 
Tuesday, March 29, 2022
Therapy, Novartis Institute for Tropical Diseases, Leadership, Developmental biology, Multimedia, Johns Hopkins, RNA splicing, United States Air Force Scientific Advisory Board, Cancer, RNA, Howard Hughes Medical Institute, Molecular biology, View, Johns Hopkins School of Medicine, Technology, NIBR, Doctor of Philosophy, Drug discovery, SAB, Chemical biology, Department, Genetics, Cirrhosis, Biomedical Research, Medical device, Pharmaceutical industry, Biochemistry, Research, Novartis

SHANGHAI and WARREN, N.J., March 29, 2022 /PRNewswire/ -- Laekna Therapeutics, a clinical-stage global biotechnology companyannounced today the appointment of Jeff Porter, Ph.D. as the Chairman of its Scientific Advisory Board (SAB).

Key Points: 
  • SHANGHAI and WARREN, N.J., March 29, 2022 /PRNewswire/ -- Laekna Therapeutics, a clinical-stage global biotechnology companyannounced today the appointment of Jeff Porter, Ph.D. as the Chairman of its Scientific Advisory Board (SAB).
  • He will work with several other senior industrial and academic leaders to provide scientific governance and guide Laekna Therapeutics in developing the next generation of medicines to treat cancer and liver fibrosis.
  • "We are honored to have Dr. Porter join us and lead our Scientific Advisory Board.
  • "Laekna Therapeutics has an exciting and globally competitive pipeline of potential new therapies and early projects, " said Dr. Porter.

Mt. Washington Pediatric Hospital Celebrates 25 Years in the Capital Region

Retrieved on: 
Thursday, March 24, 2022
Capital Regional Medical Center, UMMS, Mt. Washington Pediatric Hospital, Intensive care unit, Rehabilitation, Leadership, Diagnosis, Occupational therapy, University of Maryland Medical System, Johns Hopkins School of Medicine, Birth certificate, Prince George, CEO, Anatomical pathology, MWPH, Diabetes, High-dependency unit, Brooklyn Hospital Center, Asthma, History of the University of Maryland, College Park, JHM, Capital region, Patient, University, Partnership, Speech, Hospital, Dentistry

LARGO, Md., March 24, 2022 /PRNewswire-PRWeb/ -- Mt. Washington Pediatric Hospital (MWPH), a leader in pediatric care for 100 years, celebrates 25 years of serving families throughout the Capital Region. MWPH's Prince George's County satellite facility is located at the University of Maryland (UM) Capital Region Medical Center and is a trusted provider of family-focused, coordinated care to all children, including those with serious, chronic, and complex medical conditions.

Key Points: 
  • Washington Pediatric Hospital (MWPH), a leader in pediatric care for 100 years, celebrates 25 years of serving families throughout the Capital Region.
  • MWPH has evolved to meet the needs of children and families throughout its 25 years of service in the Capital Region.
  • Washington Pediatric Hospital is an example of a partnership that has enhanced care delivery for pediatric patients in Prince George's County for 25 years," said Nathaniel Richardson, Jr., University of Maryland Capital Region Health President and CEO.
  • Washington Pediatric Hospital celebrates 100 years of providing family-focused, coordinated care to all children, including those with serious, chronic, or complex medical needs.

Co-Diagnostics, Inc. Makes Strategic Additions to Scientific Advisory Board

Retrieved on: 
Thursday, March 17, 2022
ARUP Laboratories, Company, Private Securities Litigation Reform Act, Medicine, PSLRA, Principal, Tron Lightcycle Power Run, Johns Hopkins University, Biochemistry, DNA, College, Medical microbiology, Growth, List of pathologists, Pathology, M.D, College of American Pathologists, Research, SEC, Doctor of Philosophy, Risk, BioMérieux, Coronavirus Scientific Advisory Board (Turkey), CSO, ASM, Laboratory, CEO, Severe acute respiratory syndrome coronavirus 2, U.S. Securities and Exchange Commission, RNA, Johns Hopkins School of Medicine, Kyoto University, Infectious Diseases Society of America, SALT, Security (finance), Technology, Infection, Acquisition, Time, American Academy, University of Utah, SAB, Yale University, Saliva, Annual report, University, Division, Pharmaceutical industry, Management, Medical device

SALT LAKE CITY, March 17, 2022 /PRNewswire/ --Co-Diagnostics, Inc.(Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, is pleased to announce today that it has made several strategic additions to its Scientific Advisory Board ("SAB").

Key Points: 
  • SALT LAKE CITY, March 17, 2022 /PRNewswire/ --Co-Diagnostics, Inc.(Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, is pleased to announce today that it has made several strategic additions to its Scientific Advisory Board ("SAB").
  • Dwight Egan, CEO of Co-Diagnostics, remarked, "We are honored to have such talented and renowned industry leaders advising Co-Diagnostics.
  • Dr. Wittwer, cofounder and CSO of Idaho Technology/BioFire since 1990 and board chairman of BioFire during its acquisition by bioMerieux in 2014, is professor emeritus of Pathology at the University of Utah.
  • She has worked in the United States and Japan directing strategic investments in new technology.

Genomic and Cancer Diagnostic Veteran Bill Stevens, Joins Capsulomics Leadership Team

Retrieved on: 
Thursday, March 17, 2022
Johns Hopkins University, Esophageal cancer, Adenocarcinoma, CLIA, DNA, Diagnosis, Growth, Johns Hopkins School of Medicine, Cancer, Delfi, DNA methylation, LDT, Barrett's esophagus, Health, Industry, Technology, Physician, Degenerative disease, FDA, Patient, Prognosis, Medical imaging

"I am thrilled to join the leadership team at Capsulomics.

Key Points: 
  • "I am thrilled to join the leadership team at Capsulomics.
  • Capsulomics is similar to both Delfi and PGDx as their focus is on the early detection of cancer using technology that was developed by physicians at Johns Hopkins Medicine.
  • Capsulomics Inc. is a life sciences company focused on the development and commercialization of diagnostic tests for cancer prevention.
  • Preliminary studies suggest that Capsulomics' diagnostics can detect more esophageal diseases, including early cancers, and predict progression more accurately than all existing esophageal cancer or precancer diagnostics currently available.

Cue Health's Pioneering Smart Home Lab and PCR-quality COVID-19 Test Now Available in Canada

Retrieved on: 
Wednesday, March 16, 2022
Health Canada, Federal Food, Drug, and Cosmetic Act, SEC, Trial of the century, PSAR, Major League Baseball, Interim order, EUA, Minister for Health (House of Lords), Air Canada, Medical device, Cue, Work, MLB, School, E-commerce, Partnership, Health Sciences Authority, FDA, Nasdaq, Multimedia, Form, Risk, COVID-19, Reader, Vertically transmitted infection, Interim, Men's Health, Diagnosis, Sale, Emergency Use Authorization, Use, NAAT, Sport, National, Union, Mayo Clinic, Travel, CEO, Severe acute respiratory syndrome coronavirus 2, Hand, Johns Hopkins School of Medicine, Virus, CE, Import, COVID-19 testing, SAN, Central Drugs Standard Control Organisation, National Basketball Association, NBA, Pharmaceutical industry, Google, Health

SAN DIEGO, March 16, 2022 /PRNewswire/ -- Cue Health ("Cue") (Nasdaq: HLTH), the healthcare technology company behind the most accurate at-home COVID-19 test* in the U.S., today announced that its molecular COVID-19 test is now available to individual consumers in Canada. The Cue Health Monitoring System (Reader) and Cue's molecular COVID-19 test for home, can be accessed through Cue's eCommerce site and in-app shop. Canadian consumers can also sign up for the Cue+ Foundation membership, which provides users with unlimited access to Cue's supervised COVID-19 test by virtual proctor in English and French for travel, work, or school; ten (10) COVID-19 tests are included in each membership, as well as ongoing discounts on Cue products.

Key Points: 
  • SAN DIEGO, March 16, 2022 /PRNewswire/ --Cue Health ("Cue") (Nasdaq: HLTH), the healthcare technology company behind the most accurate at-home COVID-19 test * in the U.S., today announced that its molecular COVID-19 test is now available to individual consumers in Canada.
  • The Cue Health Monitoring System (Reader) and Cue's molecular COVID-19 test for home, can be accessed through Cue's eCommerce site and in-app shop.
  • Last year, Cue announced a partnership with Air Canada to provide U.S.-based passengers with access to Cue's molecular COVID-19 test for their travel needs.
  • Cue Health's first-of-its-kind COVID-19 test was the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without a prescription and physician supervision.

Dr. Keith Ablow to U.S. Government: Make Curcumin Available Free of Charge

Retrieved on: 
Tuesday, March 15, 2022
Depression, COVID-19, Violence, Johns Hopkins School of Medicine, Book, Curcumin, Tramadol, Inside Edition, Recidivism, Government, Today (American TV program), Life, Adult, Mental, Federation, National Institute, National Institute of Mental Health, The Washington Post, The New York Times, Ketamine, Crime, Brown University, Psychology, CBS, Fox & Friends, Neuroscience, Pharmaceutical industry, Dietary supplement

The role of Ultram as an extremely effective treatment for depression is now proven.

Key Points: